167 related articles for article (PubMed ID: 35195858)
21. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
22. GAB2 amplifications refine molecular classification of melanoma.
Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
[TBL] [Abstract][Full Text] [Related]
23. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
24. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
25. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
26. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
27. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites.
Sekine S; Nakanishi Y; Ogawa R; Kouda S; Kanai Y
Virchows Arch; 2009 May; 454(5):513-7. PubMed ID: 19319568
[TBL] [Abstract][Full Text] [Related]
28. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
29. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
30. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
31.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
32. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
33. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
34. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
[TBL] [Abstract][Full Text] [Related]
35. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
[TBL] [Abstract][Full Text] [Related]
36. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
37. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
38. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
[TBL] [Abstract][Full Text] [Related]
39. Mutational Profile of Driver Genes in Brazilian Melanomas.
Vicente ALSA; Crovador CS; Macedo G; Scapulatempo-Neto C; Reis RM; Vazquez VL
J Glob Oncol; 2019 Nov; 5():1-14. PubMed ID: 31756131
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
